Edinburgh Uni Crohn's Trigger Breakthrough | AcademicJobs
Explore the University of Edinburgh's latest research revealing Crohn's lymphoid aggregates as a trigger for fibrosis, paving the way for new anti-scarring treatments in IBD.
No reviews yet. Be the first to rate Shahida!
Dr Shahida Din is an Honorary Senior Clinical Lecturer in the School of Population Health Sciences at the University of Edinburgh. She holds the position of Consultant Gastroenterologist at the Western General Hospital in Edinburgh, where she has a specialist interest in Inflammatory Bowel Disease. Dr Din completed her medical and basic science degrees at the University of Dundee. She undertook postgraduate training in Edinburgh, including a PhD in the molecular biology of colorectal cancer. She was appointed as a consultant gastroenterologist in 2015.
Dr Din leads clinical research initiatives in gastroenterology and inflammatory bowel disease. Her work includes systematic reviews on the risks associated with placebos in randomised controlled trials for ulcerative colitis and Crohn’s disease, published in The Lancet Gastroenterology & Hepatology in 2024. She has contributed to numerous publications on IBD therapies, nomenclature, surveillance, and related topics. Dr Din serves as Chair of the British Society of Gastroenterology Inflammatory Bowel Disease committee and leads initiatives to improve patient care through data in collaboration with Crohn’s & Colitis UK. She is involved in projects such as the Gut Cell Atlas and has presented on related research at professional meetings. Dr Din maintains an active research profile with outputs in peer-reviewed journals on topics including combination therapies in refractory Crohn’s disease and pregnancy outcomes in IBD.
Professional Email: null
Explore the University of Edinburgh's latest research revealing Crohn's lymphoid aggregates as a trigger for fibrosis, paving the way for new anti-scarring treatments in IBD.
Explore the University of Edinburgh's latest Crohn’s breakthrough identifying immune cell clusters as fibrosis triggers, with implications for treatments and academic careers in IBD research.